Drug Database · Clinicians

Phytomenadione

Also known as: phytonadione (US name)

Brands (26) Ambivit K, Hema-K, Kedion…Show all

US brand (reference label): Vitamin K1; not a Philippine-registered brand.

Vitamin K; Warfarin Reversal Agent US FDA class
Antihemorrhagic (vitamin k); Vitamin k and other hemostatics; and others PH FDA category

Rx · Prescription drug29 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID e8808230-2c44-44c6-8cab-8f29b6b34051, version date August 9, 2026 (Vitamin K1 · Hospira, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Anticoagulant-induced hypoprothrombinemia deficiency caused by coumarin or indanedione derivatives.
  • Hypoprothrombinemia due to antibacterial therapy.
  • Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of…
  • Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.
  • Vitamin K 1 Injection is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Vitamin K 1 Injection is a vitamin K replacement indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.

  • Anticoagulant-induced hypoprothrombinemia deficiency caused by coumarin or indanedione derivatives. (1.1)
  • Hypoprothrombinemia due to antibacterial therapy. (1.1)
  • Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis. (1.1)
  • Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. (1.1) Vitamin K 1 Injection is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates. (1.2) 1.1 Treatment of Hypoprothrombinemia Due to Vitamin K Deficiency or Interference Vitamin K 1 Injection is indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity:
  • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives;
  • hypoprothrombinemia due to antibacterial therapy;
  • hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis;
  • other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. 1.2 Prophylaxis and Treatment of Vitamin K-Deficiency Bleeding in Neonates Vitamin K 1 Injection is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates.

Contraindications

4 CONTRAINDICATIONS Hypersensitivity to phytonadione or any other component of this medication [see Warnings and Precautions (5.1)]. Hypersensitivity to any component of this medication. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • Administer Vitamin K 1 Injection by the subcutaneous route, whenever possible. (2.1)
  • • When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute. (2.1)
2.1 Dosing Considerations

2.1 Dosing Considerations Whenever possible, administer Vitamin K 1 Injection by the subcutaneous route [see Boxed Warning]. When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute [see Warnings and Precautions (5.1)]. Monitor international normalized ratio (INR) regularly and as clinical conditions indicate.

Use the lowest effective dose of Vitamin K 1 Injection. The coagulant effects of Vitamin K 1 Injection are not immediate; improvement of INR may take 1 to 8 hours. Interim use of whole blood or component therapy may also be necessary if bleeding is severe. Whenever possible, administer benzyl alcohol-free phytonadione formulations in pediatric patients [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

When Vitamin K 1 Injection is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Vitamin K 1 Injection is not a clotting agent, but overzealous therapy with Vitamin K 1 Injection may restore conditions which originally permitted thromboembolic phenomena.

Dosage should be kept as low as possible, and INR should be checked regularly as clinical conditions indicate.

2.2 Recommended Dosage for Coagulation Disorders from Vitamin K Deficiency or Interference

2.2 Recommended Dosage for Coagulation Disorders from Vitamin K Deficiency or Interference The recommended dosage of Vitamin K 1 Injection is based on whether the hypoprothrombinemia is anticoagulant-induced (e.g., due to coumarin or indanedione derivatives) or non-anticoagulant-induced (e.g., due to antibiotics; salicylates or other drugs; factors limiting absorption or synthesis) as follows:

  • Anticoagulant-Induced Hypoprothrombinemia: Vitamin K 1 Injection 2.5 mg to 10 mg or more subcutaneously, intramuscularly, or intravenously. Up to 25 mg to 50 mg may be administered as a single dose. Repeated large doses of Vitamin K 1 Injection are not warranted in liver disease if the initial response is unsatisfactory. Failure to respond to Vitamin K 1 Injection may indicate that the condition being treated is inherently unresponsive to Vitamin K 1 Injection.
  • Hypoprothrombinemia Due to Other Causes (Non-Anticoagulation-Induced Hypoprothrombinemia): Vitamin K 1 Injection 2.5 mg to 25 mg or more intravenously, intramuscularly, or subcutaneously. Up to 50 mg may be administered as a single dose. Evaluate INR after 6 to 8 hours, and repeat dose if INR remains prolonged. Modify subsequent dosage (amount and frequency) based on the INR or clinical condition.
2.3 Recommended Dosage for Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in…

2.3 Recommended Dosage for Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in Neonates Prophylaxis of Vitamin K-Deficiency Bleeding in Neonates The recommended dosage of Vitamin K 1 Injection is 0.5 mg to 1 mg within one hour of birth for a single dose. Treatment of Vitamin K Deficiency Bleeding in Neonates The recommended dosage of Vitamin K 1 Injection is 1 mg given either subcutaneously or intramuscularly.

Consider higher doses if the mother has been receiving oral anticoagulants. A failure to respond (shortening of the INR in 2 to 4 hours) may indicate another diagnosis or coagulation disorder.

2.4 Directions for Dilution

2.4 Directions for Dilution Dilute Vitamin K 1 Injection with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and Sodium Chloride Injection. Avoid use of other diluents that may contain benzyl alcohol, which can cause serious toxicity in newborns or low birth weight infants [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

When diluted, start administration of Vitamin K 1 Injection immediately after dilution. Discard unused portions of diluted solution as well as unused contents of the ampul. Protect Vitamin K 1 Injection from light at all times. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of Vitamin K 1 Injection for prophylaxis and treatment of vitamin K deficiency have been established in neonates. Use of phytonadione injection for prophylaxis and treatment of vitamin K deficiency is based on published clinical studies. Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and infants in the intensive care unit who received drugs containing benzyl alcohol as a preservative.

In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse.

Preterm, low birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. When prescribing Vitamin K 1 Injection in infants consider the combined daily metabolic load of benzyl alcohol from all sources including Vitamin K 1 Injection (Vitamin K 1 Injection contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol.

The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [see Warnings and Precautions (5.2)]. Whenever possible, use preservative-free phytonadione formulations in neonates. The preservative benzyl alcohol has been associated with serious adverse events and death in pediatric patients.

Premature and low birth weight infants may be more likely to develop toxicity.

Administration

2.4 Directions for Dilution Dilute Vitamin K 1 Injection with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and Sodium Chloride Injection. Avoid use of other diluents that may contain benzyl alcohol, which can cause serious toxicity in newborns or low birth weight infants [see Warnings and Precautions (5.2) , Use in Specific Populations (8.4) ]. When diluted, start administration of Vitamin K 1 Injection immediately after dilution. Discard unused portions of diluted solution as well as unused contents of the ampul. Protect Vitamin K 1 Injection from light at all times. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

US FDA label

Dosage forms

Philippines

  • Solution for injection: 1 mg/0.5 mL, 10 mg/mL

Registered products in the Philippines

29 products registered with the Food and Drug Administration (FDA) Philippines list Phytomenadione as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products29
Philippine FDA-registered products for Phytomenadione
Package insert
AephytoPhytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)USP Type I Amber Colored Glass Ampoule x 1 mL (net content) (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Dynasty PharmaceuticalsImporter: Euro-Care Products Philippines
DRP-8357-03
Sep 9, 2029
Ambivit KPhytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)Amber Glass Ampoule x 1 mL (Box of 5’s, 10’s and 50’s)
Rx
Farbe Firma Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-9445
Jan 9, 2030
Ambivit KPhytomenadione
10mg/mL Solution for Injection (IM/IV/SC)Type I Amber Glass Ampoule x 1mL in PVC Tray (Box of 10's)
Rx
Cisen Pharmaceutical Co., LtdChina
AMB HK Enterprises, Inc.
DRP-17325
Nov 14, 2030
CycominPhytomenadione
10 mg/mL Solution for Injection (I.M./I.V.)Amber Ampoule x 1 mL (Box of 10's)
Rx
Panpharma GmbHGermany
Duopharma Trade Phils., Inc.
DR-XY15470
May 10, 2031
DynaphytoPhytomenadione
10 mg/mL Solution for Injection (I.V./I.M./S.C.)USP Type I Amber Glass Ampoule X 1 mL (Box of 10's)
Rx
Anhui Changjiang Pharmaceutical Co., Ltd.China
Dynasty PharmaceuticalsImporter: Aglobal Care, Inc.
DRP-7266-01
Jun 22, 2031
ExakionPhytomenadione
10 mg/mL Solution for Injection (I.M./I.V./S.C.)USP Type I Amber Glass Ampoule in 2 mL (net content) Box of 10 ampoules in plastic tray; USP Type I Amber Glass Ampoule in 1 mL (net content) Box of 10 ampoules in plastic tray
Rx
Harmann Pharmaceutical Lab. (Pvt.) Ltd.Pakistan
Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-9329-01
Aug 23, 2027
Hema-KPhytomenadione
10 mg/mL Solution for Injection (I.M./I.V.)1 mL-net content USP Type I Amber Glass Ampoule (Box of 10's)
Rx
Ciron Drugs & Pharmaceuticals Pvt. Ltd.India
Phil Pharmawealth, Inc.Trader: Oboi Laboratories
DR-XY48971
Jan 3, 2029
Hema-KPhytomenadione
10mg/mL Solution for Injection (IM/IV/SC)Amber Glass Ampoule x 1mL Box of 100's
Rx
Taiwan Biotech Co., Ltd.China
Phil Pharmawealth, Inc.
DRP-3117
Oct 28, 2027
HematronPhytomenadione
10 mg/mL Solution for Injection (I.M./I.V./S.C.)1 mL USP Type 1 Amber Glass Ampoule mounted in clear and colorless PVC tray x 10 ampoules (Box of 50 ampoules)
Rx
Dai Han Pharm. Co., Ltd.Korea
JMN Brothers Pharma Limited Inc.
DRP-7353
Sep 29, 2027
HemogenPhytomenadione
10 mg/ mL Solution for Injection (I.M./I.V./S.C.)Type I amber glass ampoule (Box of 50's)
Rx
Daewon Pharm. Co., Ltd.Korea
Altomed Pharmaceuticals, Inc.Importer: Largen Med., Inc.
DRP-1698-01
Mar 1, 2027
Ka-PhytPhytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)USP Type I Amber Colored Glass Ampoule x 1 mL (net content) (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Asianmeds, Inc.Importer: Euro-Care Products Philippines
DRP-8357-04
Sep 9, 2029
KedionPhytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)Type I Amber Glass Ampoule x 1 mL (Box of 10's)
Rx
Suicheng Pharmaceutical Co., Ltd.China
AGlobal Care, Inc.Importer: Aglobal Care, Inc.
DR-XY45137
Jul 21, 2027
KedionPhytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)Type I Amber Glass Ampoule x 1 mL (Box of 1 0's)
Rx
Suicheng Pharmaceutical Co., Ltd.China
AGlobal Care, Inc.
DRP-12946
Jul 21, 2027
Konakion MMPhytomenadione
10 mg/mL Solution for Injection (IV)Amber Glass Ampoule x 1 mL (Box of 5's)
Rx
CENEXI SASFrance
ZUELLIG PHARMA CORPORATIONTrader: Cheplapharm Arzneimittel GmbH
DR-XY2508
Oct 9, 2028
KonamedPhytomenadione
10 mg/mL Solution for Injection (I.M./I.V./S.C.)USP Type I Amber Colored Glass Ampoule x 1 mL (net content) (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Asianmeds, Inc.Importer: Euro-Care Products Philippines
DRP-8357-01
Sep 9, 2029
MenadonPhytomenadione
10 mg/mL Solution for Injection (I.M./I.V./S.C.)USP Type I amber coloured glass ampoule x 1 mL (Box of 10's)
Rx
Suicheng Pharmaceutical Co., Ltd.China
Aglobal Care, Inc.
DRP-12960
Nov 9, 2027
Menaright FortePhytomenadione
10 mg/mL Solution for Injection (IV)1 mL amber glass ampoule (Box of 5's)
Rx
Norris Medicines LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-6857
Oct 10, 2029
PhytobasPhytomenadione
10 mg/mL Solution for Injection (I.M/I.V/S.C)USP Type I amber glass ampoule in 2 mL (net content); Box of 10 ampoules in plastic tray USP Type I amber glass ampoule in 1 mL (net content); Box of 10 ampoules in plastic tray
Rx
Harmann Pharmaceutical Lab. (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-9329
Aug 23, 2027
PhytocarePhytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)USP Type I Amber Colored Glass Ampoule X 1 mL (net content) (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Euro-Care Products Philippines
DRP-8357
Sep 9, 2029
PhytodonePhytomenadione (Vitamin K1)
10mg/mL Solution for Injection (IM/IV/SC)Type I Amber Glass Ampoule with White Ring on Neck ImL in PVC Tray x 10's (Box of 10's)
Rx
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International, Inc.
DRP-16553
Apr 25, 2030
Phytome-K-10Phytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)USP Type I amber glass ampoule x 1 mL in a plastic tray x 10's (Box of 10's)
Rx
Merit Organics Ltd.India
Khriz Pharma Trading Inc.
DRP-17230
Oct 23, 2030
PhytomenPhytomenadione
10 mg/mL Solution for Injection (I.V./I.M./S.C.)1 mL USP Type I Amber Glass Ampoule (Box of 10's)
Rx
Anhui Changjiang Pharmaceutical Co., Ltd..China
Aglobal Care, Inc.
DRP-7266
Jun 18, 2030
PhytomenasaphPhytomenadione (Vitamin K1)
10mg/mL Solution for Injection (IM/IV/SC)Amber Colored Ampoule x 1 mL (Box of 10's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11226
Feb 15, 2027
PhytoradPhytomenadione
10 mg/mL Solution for Injection (IM/IV/SC)USP Type I Amber Colored Glass Ampoule x 1 mL (net content) (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
HLM Pharmaceutical Inc.Importer: Euro-Care Products Philippines
DRP-8357-02
Sep 9, 2029
PhytosavePhytomenadione
10 mg / mL Solution for Injection (I.V./I.M./S.C.)1 mL USP Type I Amber Glass Ampoule (Box of 10's)
Rx
Anhui Changjiang Pharmaceutical Co., Ltd.China
Savelink Pharma and Trading Co.Importer: AGlobal Care, Inc.
DRP-7266-04
Jun 18, 2030
PhytostatPhytomenadione
1 mg/0.5mL Solution for Injection (I.M./I.V./S.C.)USP Type I Amber Glass Ampoule x 0.5 mL (Box of 10's(
Rx
Swiss Parenterals, Ltd.India
Endure Medical, Inc.
DR-XY41391
Nov 28, 2027
PhytovuePhytomenadione
10 mg / mL Solution for Injection (IM/IV/SC)Amber Glass Ampoule x 1 mL (Box of 10’s)
Rx
Farbe FirmaIndia
CV Clearvue Pharma, Inc.Importer: AMB HK Enterprises Inc.
DRP-9445-02
Jan 9, 2030
PytogenPhytomenadione
10 mg/mL Solution for Injection (I.M./I.V./S.C.)Type I Amber Glass Ampoule (Box of 50's)
Rx
Daewon Pharm. Co., Ltd.Republic of Korea
Pharma King DistributorImporter: Largen Med Inc.
DRP-1698
Mar 1, 2027
RaphydionePhytomenadione
10 mg/mL Solution For Injection (I.M/I.V/S.C)Type I Amber Glass Ampoule x 1 mL (Box of 10's)
Rx
Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China
Raquel Abbas Pharma Inc.
DRP-18970
Oct 8, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: 1 mg/0.5 mL and 10 mg/mL single-dose ampuls. Injection: 1 mg/0.5 mL and 10 mg/mL single-dose ampuls. (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative: Use benzyl alcohol-free phytonadione formulations in neonates and infants, if available. (5.2)
  • • Cutaneous Reactions: May occur with parenteral use. Discontinue drug and manage medically. (5.3)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Fatal and severe hypersensitivity reactions, including anaphylaxis, have occurred with intravenous or intramuscular administration of Vitamin K 1 Injection. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. These reactions have included shock, cardiorespiratory arrest, flushing, diaphoresis, chest pain, tachycardia, cyanosis, weakness, and dyspnea.

Administer Vitamin K 1 Injection subcutaneously whenever feasible. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified [see Dosage and Administration (2.1)].

5.2 Risk of Serious Adverse Reaction in Infants due to Benzyl Alcohol Preservative

5.2 Risk of Serious Adverse Reaction in Infants due to Benzyl Alcohol Preservative Use benzyl alcohol-free phytonadione formulations in neonates and infants, if available. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol‑preserved drugs, including Vitamin K 1 Injection.

The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. When prescribing Vitamin K 1 Injection in infants, consider the combined daily metabolic load of benzyl alcohol from all sources including Vitamin K 1 Injection (contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol.

The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [see Use in Specific Populations (8.1, 8.2 and 8.4)].

5.3 Cutaneous Reactions

5.3 Cutaneous Reactions Parenteral administration of vitamin K replacements (including Vitamin K 1 Injection) may cause cutaneous reactions. Reactions have included eczematous reactions, scleroderma-like patches, urticaria, and delayed-type hypersensitivity reactions. Time of onset ranged from 1 day to a year after parenteral administration.

Discontinue Vitamin K 1 Injection for skin reactions and institute medical management.

5.4 Aluminum Toxicity

5.4 Aluminum Toxicity WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Anticoagulants Vitamin K 1 Injection may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of Vitamin K 1 Injection are used. Should this occur, higher doses of anticoagulant therapy may be needed when resuming anticoagulant therapy, or a change in therapy to a different class of anticoagulant may be necessary (i.e., heparin sodium). Vitamin K 1 Injection does not affect the anticoagulant action of heparin. Anticoagulants: May induce temporary resistance to prothrombin-depressing anticoagulants. (7)

Adverse reactions

Adverse reactions (US label) US FDA label

The following serious adverse reactions are described elsewhere in the labeling:

  • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
  • Cutaneous Reactions [see Warnings and Precautions (5.3)] Most common adverse reactions are cyanosis, diaphoresis, dizziness, dysgeusia, dyspnea, flushing, hypotension and tachycardia. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1‑800‑438‑1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Vitamin K 1 Injection. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiac Disorders: Tachycardia, hypotension. General Disorders and Administration Site Conditions: Generalized flushing; pain, swelling, and tenderness at injection site. Hepatobiliary Disorders: Hyperbilirubinemia. Immune System Disorders: Fatal hypersensitivity reactions, anaphylactic reactions. Neurologic: Dysgeusia, dizziness.

Pulmonary: Dyspnea. Skin and Subcutaneous Tissue Disorders: Erythema, pruritic plaques, scleroderma-like lesions, erythema perstans. Vascular: Cyanosis.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Vitamin K 1 Injection contains benzyl alcohol, which has been associated with gasping syndrome in neonates. The preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants. If Vitamin K 1 Injection is needed during pregnancy, consider using a benzyl alcohol-free phytonadione formulation [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

Published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes [see Data]. There are maternal and fetal risks associated with vitamin K deficiency during pregnancy [see Clinical Considerations]. Animal reproduction studies have not been conducted with phytonadione.

The estimated background risk for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations Disease-associated Maternal and/or Embryo/Fetal Risk Pregnant women with vitamin K deficiency hypoprothrombinemia may be at an increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. Subclinical maternal vitamin K deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage.

Data Human Data Phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. Administration of vitamin K 1 to pregnant women shortly before delivery increased both maternal and cord blood concentrations. Published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy.

However, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding. Animal Data In pregnant rats receiving vitamin K 1 orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer.

Mechanism of action

12.1 Mechanism of Action Vitamin K 1 Injection aqueous dispersion of vitamin K 1 for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the post‑translational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X.

The resulting gamma-carboxy-glutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood. In normal animals and humans, phytonadione is virtually devoid of activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K dependent clotting factors.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The action of the aqueous dispersion, when administered intravenously, is generally detectable within an hour or two and hemorrhage is usually controlled within 3 to 6 hours. A normal INR may often be obtained in 12 to 14 hours.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Phytonadione is readily absorbed following intramuscular administration. Distribution After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Elimination Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Phytomenadione 10 mg/mL, 1 mL Ampule₱12.95–₱48.77Reference ₱16.77per ampuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Phytomenadione (phytonadione, vitamin K1)
PNF listingOral/Inj.: 2 mg/0.2 mL pediatric ampul (IM, IV, PO) (as mixed micelle)
PNF listingInj.: 10 mg/mL, 1 mL ampul (IM, IV, SC) (as aqueous colloidal solution with benzyl alcohol)
PNF listingInj.: 10 mg/mL, 1 mL ampul (IM, IV, SC) (as mixed micelle)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Vitamin K1 · Hospira, Inc. [US FDA-approved label, version 23, August 9, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8808230-2c44-44c6-8cab-8f29b6b34051
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .